WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced that the U.S. Food and Drug Administration (FDA) has ...

Regenerative medicine, which uses iPS (induced pluripotent stem) cells and other materials to cure diseases for which there ...

The trial will assess the therapy’s pharmacokinetics, pharmacodynamics and safety, as well as its impact on disease activity.

KYOTO—Researchers have safely transplanted nerve cells generated from induced pluripotent stem (iPS) cells into the brains of ...

Lynae Darbes, PhD, discusses what her research results mean when it comes to implementation of self-testing and counselling ...

The VISTA* study is set to commence in Q2 2025. For further details, visit the UK Clinical Trials Registry for Integrated Research Application System (IRAS) project 1008088. Prof Mark Middleton ...

has granted Clinical Trial Application (CTA) approval for the first-in-human Phase I/IIa clinical trial of ITOP1, the company's lead 'off-the-shelf' cancer vaccine. ITOP1 is a precision cancer ...

has granted Clinical Trial Application (CTA) approval for the first-in-human Phase I/IIa clinical trial of ITOP1, the company's lead 'off-the-shelf' cancer vaccine. ITOP1 is a precision cancer vaccine ...

The VISTA* study is set to commence in Q2 2025. For further details, visit the UK Clinical Trials Registry for Integrated Research Application System (IRAS) project 1008088. Prof Mark Middleton, Chief ...